Human Papillomavirus Working Group


Dr. Elizabeth Stier, HPV Chair
Boston Medical Center

Vice Chair

Dr. Mark Einstein, HPV Vice Chair
Rutgers New Jersey Medical School

HPV is the most common sexually transmitted disease, infecting at least 75% of sexually active adults at some point in their lifetime. HPV causes most of the cancers of the anus and cervix, many head & neck cancers, as well as other cancers. The HPV Working Group has done several important studies that have changed the way in which HIV-positive patients with HPV-associated disease are treated. In one clinical study, our group showed that infrared coagulation (IRC) is a well-tolerated treatment of high-grade anal intra-epithelial neoplasia, a precursor to anal cancer.

The current goals of the HPV WG are to:

  1. Evaluate the safety and efficacy of new methods of prevention and treatment of anal and cervical cancers and cancer precursors in HIV-positive patients.
  2. Determine which proteins and genes in the blood and tumor specimens (also known as biologic correlates) will help predict a patient’s prognosis and response to treatment. Knowledge gained from this will be used to develop and test new treatment strategies.
  3. Train clinicians in high-resolution anoscopy to expand expertise and availability of this procedure within the AMC.








Current Protocols:

AMC-088 A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women
AMC-092 A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons